Patents by Inventor Rajamannar Thennati
Rajamannar Thennati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240020543Abstract: The present disclosure provides methods and systems for hyperparameter tuning and benchmarking.Type: ApplicationFiled: October 13, 2021Publication date: January 18, 2024Inventors: Rajamannar THENNATI, Vinod Sampatrao BURADE, Muthukumaran NATARAJAN, Dhiren Rameshchandra JOSHI, Manish Harendraprasad GANDHI, Chandulal Thakarshibhai JIVANI, Abhishek TIWARI, Krunal Harishbhai SONI
-
Patent number: 11873328Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: August 1, 2022Date of Patent: January 16, 2024Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Patent number: 11866477Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: August 12, 2022Date of Patent: January 9, 2024Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Patent number: 11819501Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.Type: GrantFiled: April 4, 2022Date of Patent: November 21, 2023Inventors: Alpesh Goyani, Deepak Singodia, Bhaskar Pallerla, Sudeep Kumar Agrawal, Subhas Balaram Bhowmick, Rajamannar Thennati
-
Publication number: 20230338366Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.Type: ApplicationFiled: April 24, 2023Publication date: October 26, 2023Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Alpesh GOYANI, Deepak SINGODIA, Bhaskar PALLERLA, Sudeep Kumar AGRAWAL, Subhas Balaram BHOWMICK, Rajamannar THENNATI
-
Publication number: 20230241178Abstract: The present invention relates to long acting glucagon-like peptide-1 and human glucose-dependent insulinotropic polypeptide (GIP) agonist polypeptides which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.Type: ApplicationFiled: June 21, 2021Publication date: August 3, 2023Inventors: Rajamannar THENNATI, Vinod Sampatrao BURADE, Muthukumaran NATARAJAN, Dhiren Rameshchandra JOSHI, Manish Harendraprasad GANDHI, Chandulal Thakarshibhai JIVANI, Abhishek TIWARI, Krunal Harishbhai SONI
-
Publication number: 20230098076Abstract: The present disclosure provides a process for preparation of 3,6-dichlorocyano pyrazine, 3,6-dioxopiperizine derivatives and production of favipiravir via ammonia or amine-mediated cyclization and chlorination using POCl3 in the presence of pyridine or PCl5. [Formula] wherein in 3,6-dioxopiperazine derivatives (III), X is CN, CONH2 or COOR2?, R1, R2 and R2? are individually selected from H, C1-C12 alkyl, COOR3 and SO2R3 wherein R3 is substituted or unsubstituted linear or branched lower alkyl.Type: ApplicationFiled: June 11, 2021Publication date: March 30, 2023Inventors: Raji Reddy CHADA, Amol DNYANDEV PATIL, Subbarao MUPPIDI, Nagender PUNNA, Ramachandra Reddy DONTHIRI, Ajay K SINGH, Prathama S MAINKAR, Chandrasekhar SRIVARI, Rajamannar THENNATI
-
Publication number: 20220402992Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: ApplicationFiled: August 12, 2022Publication date: December 22, 2022Inventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Publication number: 20220402991Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: ApplicationFiled: August 1, 2022Publication date: December 22, 2022Inventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Patent number: 11485766Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: December 28, 2020Date of Patent: November 1, 2022Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Publication number: 20220296618Abstract: The present invention relates to the use of a compound of Formula (I) for the treatment of a wound, impaired healing of a wound, hair loss on and around a wound, scars and/or wrinkles on and around a wound, psoriasis, and any combination thereof. The present inventions also relates to methods of using such compounds, and to compositions and kits containing the compound. (I) X? is any halogen.Type: ApplicationFiled: November 23, 2020Publication date: September 22, 2022Inventors: Srigiridhar KOTAMRAJU, Surendar Reddy BATHULA, Ramakrishna SISTLA, Anthony ADDLAGATTA, Rajamannar THENNATI, Altab SHAIKH, Aruna JANGUM, Rajendra SANGARAJU, Praveen Kumar NEELI, Kuncha MADHUSUDANA, Singuru GAJALAKSHMI
-
Patent number: 11447535Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: April 5, 2019Date of Patent: September 20, 2022Assignee: Sun Pharmaceutical Industries LimitedInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Publication number: 20220226308Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.Type: ApplicationFiled: April 4, 2022Publication date: July 21, 2022Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Alpesh GOYANI, Deepak SINGODIA, Bhaskar PALLERLA, Sudeep Kamar AGRAWAL, Subhas Balaram BHOWMICK, Rajamannar THENNATI
-
Publication number: 20220153802Abstract: The present invention relates to a stable parenteral dosage form with a ready-to-inject sterile stable aqueous solution of cetrorelix acetate. The invention also relates to an injection device prefilled with the ready-to-inject sterile stable aqueous solution of cetrorelix acetate. The present invention relates a method of inhibiting premature luteinizing hormone surges in women undergoing controlled ovarian stimulation comprising a stable parenteral dosage form with a ready-to-inject sterile stable aqueous solution of cetrorelix acetate.Type: ApplicationFiled: October 23, 2020Publication date: May 19, 2022Inventors: Jaydip Joshi, Rakesh Thummar, Sudeep Agrawal, Subhas Balaram, Arunkumar Yadav, Rajamannar Thennati
-
Patent number: 11304942Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.Type: GrantFiled: December 6, 2019Date of Patent: April 19, 2022Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Alpesh Goyani, Deepak Singodia, Bhaskar Pallerla, Sudeep Kumar Agrawal, Subhas Balaram Bhowmick, Rajamannar Thennati
-
Patent number: 11242373Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: August 4, 2020Date of Patent: February 8, 2022Assignee: Sun Pharmaceutical Industries LimitedInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Patent number: 11234925Abstract: The present invention provides a stable, aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base. The invention also provides a method of treating the septic shock by intravenous administration of stable aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base.Type: GrantFiled: January 9, 2020Date of Patent: February 1, 2022Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Amar Rana, Rakesh Thummar, Sudeep Agrawal, Subhas Balaram Bhowmick, Rajamannar Thennati
-
Publication number: 20220000776Abstract: The present invention provides a parenteral dosage form consisting essentially of a solution filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to 3.9 and further wherein the dosage form is sterilized by subjecting the filled container to autoclaving.Type: ApplicationFiled: September 15, 2021Publication date: January 6, 2022Inventors: Samarth Kumar, Soni Maheshkumar Parasmal, Milan Mohanbhai Vasoya, Prashant Kane, Subhas Balaram Bhowmick, Rajamannar Thennati
-
Publication number: 20210353531Abstract: The present invention provides a stable, aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base. The invention also provides a method of treating the septic shock by intravenous administration of stable aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base.Type: ApplicationFiled: July 27, 2021Publication date: November 18, 2021Inventors: Amar Rana, Rakesh Thummar, Sudeep Agrawal, Subhas Balaram Bhowmick, Rajamannar Thennati
-
Patent number: 11166911Abstract: The present invention provides a parenteral dosage form consisting essentially of a solution filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to 3.9 and further wherein the dosage form is sterilized by subjecting the filled container to autoclaving.Type: GrantFiled: March 3, 2017Date of Patent: November 9, 2021Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Samarth Kumar, Soni Maheshkumar Parasmal, Milan Mohanbhai Vasoya, Prashant Kane, Subhas Balaram Bhowmick, Rajamannar Thennati